Michael Meister
Overview
Explore the profile of Michael Meister including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
115
Citations
3771
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zhao H, Liu Z, Chen H, Han M, Zhang M, Liu K, et al.
Cell
. 2024 Oct;
187(25):7314-7334.e21.
PMID: 39368477
Cellular senescence plays critical roles in aging, regeneration, and disease; yet, the ability to discern its contributions across various cell types to these biological processes remains limited. In this study,...
2.
Richtmann S, Marwitz S, Muley T, Koistinen H, Christopoulos P, Thomas M, et al.
Transl Res
. 2024 Mar;
272:177-189.
PMID: 38490536
Lung cancer has been shown to be targetable by novel immunotherapies which reactivate the immune system and enable tumor cell killing. However, treatment failure and resistance to these therapies is...
3.
Muley T, Herth F, Heussel C, Kriegsmann M, Thomas M, Meister M, et al.
Tumour Biol
. 2023 Oct;
46(s1):S219-S232.
PMID: 37840518
Background: Despite successful response to first line therapy, patients with small-cell lung cancer (SCLC) often suffer from early relapses and disease progression. Objective: To investigate the relevance of serum tumor...
4.
Muley T, Schneider M, Meister M, Thomas M, Heussel C, Kriegsmann M, et al.
Tumour Biol
. 2023 Oct;
46(s1):S163-S175.
PMID: 37840516
Background: Serum tumor markers (STM) may complement imaging and provide additional clinical information for patients with non-small cell lung cancer (NSCLC). Objective: To determine whether STMs can predict outcomes in...
5.
Lutz J, Meister M, Habbeddine M, Fiedler K, Kowalczyk A, Heidenreich R
Cancer Immunol Immunother
. 2022 Nov;
72(5):1075-1087.
PMID: 36319717
Immunotherapy has revolutionized cancer treatment in recent years. Although currently approved checkpoint inhibitors (CPIs) yield remarkable anti-tumoral responses in several cancer types, a substantial proportion of patients do not benefit...
6.
Faltus C, Lahnsteiner A, Barrdahl M, Assenov Y, Husing A, Bogatyrova O, et al.
Int J Mol Sci
. 2022 Sep;
23(18).
PMID: 36142605
Changes in DNA methylation identified by epigenome-wide association studies (EWAS) have been recently linked to increased lung cancer risk. However, the cellular effects of these differentially methylated positions (DMPs) are...
7.
Grunding A, Schneider M, Richtmann S, Kriegsmann M, Winter H, Martinez-Delgado B, et al.
Cancers (Basel)
. 2022 Sep;
14(18).
PMID: 36139614
To explore the relationship between cancer cell SREBF1 expression, lipid droplets (LDs) formation, and the sensitivity to chemotherapies, we cultured lung adenocarcinoma cells H1299 (with LD) and H1563 (without LD)...
8.
Trefzer T, Schneider M, Jechow K, Chua R, Muley T, Winter H, et al.
Cancer Res
. 2022 Jul;
82(17):3116-3129.
PMID: 35819252
Single-cell analysis of healthy lung tissue and lung cancer reveals distinct tumor cell populations, including cells with differential immune modulating capacity between smokers and never smokers, which could guide future...
9.
Yaung S, Woestmann C, Ju C, Ma X, Gattam S, Zhou Y, et al.
Cancers (Basel)
. 2022 May;
14(10).
PMID: 35626082
Monitoring treatment efficacy early during therapy could enable a change in treatment to improve patient outcomes. We report an early assessment of response to treatment in advanced NSCLC using a...
10.
Schneider M, Richtmann S, Grunding A, Wrenger S, Welte T, Meister M, et al.
Int J Oncol
. 2022 Feb;
60(4).
PMID: 35211754
Transmembrane serine protease 2 (TMPRSS2) has been intensively investigated during the current Sars‑CoV‑2 pandemic as a virus activating protease. Furthermore, is an oncogenic gene associated with several cancer entities. Co‑expression...